EMAS Position Statements and Clincial Guides
Menopause symptom management in women with dyslipidemias: An EMAS clinical guide
Worldwide, dyslipidemias are one of the leading causes of cardiovascular disease, mainly coronary heart disease [1]. Dyslipidemias are also associated with an increased risk of ischemic stroke [2]. Dyslipidemias embrace a wide constellation of lipid and lipoprotein abnormalities. Lipoproteins bind lipids and are involved in their transport. Lipid abnormalities include high serum concentrations of low-density lipoprotein (LDL) cholesterol (LDL-C) and/or triglycerides and/or low concentrations of high-density lipoprotein (HDL) cholesterol (HDL-C).Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
The European Menopause and Andropause Society (EMAS) aims to provide holistic consensus advice on the clinical management of menopausal women through its position statements and clinical guides [1]. EMAS’s healthcare model for healthy menopause covers physical, psychological and social functioning, and incorporates disability and disease [2]. This position statement sets out a model of care for the management of depressive symptoms and depressive episodes in peri- and postmenopausal women, integrating services provided by healthcare and allied professionals.
